Emmaus gains marketing authorisation for sickle cell treatment in Oman

Preview

来源: Pharmaceutical Technology

In Oman, almost 3,000 individuals have sickle cell disorders. Credit: Victor Josan / Shutterstock.com.

Emmaus Life Sciences has received the Oman Ministry of Health’s marketing authorisation for Endari (L-glutamine oral powder) for the treatment of sickle cell disease in patients aged five years and above.

The treatment reduces the serious complications associated with sickle cell disease in both adult and paediatric patients.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsInnovation in Pharmaceuticals: Anti-HIV compositions GlobalData

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Elsulfavirine in Human Immunodeficiency Virus (HIV) Infections (AIDS) GlobalData

View allCompanies IntelligenceEmmaus Life Sciences IncGCCView all

Almost 3,000 individuals in Oman have sickle cell disorders and approximately 6% carry the gene for the ailment.

The treatment has already received marketing approvals in Israel, Kuwait, Qatar, Bahrain, the UAE and the US.

Endari is offered on a named individual or early access basis in the Netherlands, Saudi Arabia and France.

The company plans to seek further approvals for the treatment in other regions with high sickle cell disease prevalence.

Emmaus focuses on discovering, developing and commercialising new therapies, including those intended to treat rare and orphan diseases.

Emmaus Life Sciences global commercialisation senior vice-president George Sekulich stated: “The Omani marketing approval for Endari is an important step forward for us in the GCC region, where we have been working closely with the local authorities, physicians and patient groups to ensure access to this innovative treatment for sickle cell disease.

“We look forward to launching Endari commercially in Oman and expanding its availability to other countries in the region.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。